Suplementary Figures with legends from Tumor-Derived TGFβ Alters the Ability of Plasmacytoid Dendritic Cells to Respond to Innate Immune Signaling

Abstract

<p>Supplementary Figures S1 through S9. (1) Supplementary Figure S1: Phenotypical characterization of pDCs in the spleen of TC-1 and B16-OVA tumor-bearing mice. (2) Supplementary Figure S2. Purification of pDCs and gene family analysis. (3) Supplementary Figure S3. pDCs infiltrating TC-1 and B16-OVA tumors exhibit a distinct transcriptomic profile. (4) Supplementary Figure S4. Purified TA-pDCs produce cytokines and chemokines following CpG-stimulation. (5) Supplementary Figure S5. B16-OVA TCM contain TGF-β and inhibit pDC activation following CpG-stimulation. (6) Supplementary Figure S6. Lack of reversibility of the TCM inhibitory effect on pDC activation following CpG-stimulation. (7) Supplementary Figure S7. TCM from pDCs deficient mice contain TGF-β and inhibit pDC activation following CpG-stimulation. (8) Supplementary Figure S8. Depletion of NK cells by NK1.1 antibody treatment and representation of NK cell subsets in the spleen of tumor-bearing mice. (9) Supplementary Figure S9. Effect of anti-TGF-β antibody treatment on the growth of TC-1 tumor.</p>